ABSTRACT
This chapter discusses payer segmentation and has engaged in a detailed segmentation of the global payer environment on the basis of common underlying principles and cost management philosophies. It describes the essential characteristics of competitive insurance-based systems, therapeutic referencing systems, health economics-driven systems and emerging cash markets. The chapter describes the four key global payer archetypes that form the basis for global segmentation. Health economics has been the established basis for national and regional healthcare funding decision making in Australia, Canada and the UK for many years. The determination of price premium over the selected comparator is generally based on a systematic assessment of clinical added value in terms of efficacy and safety by typical therapy area specific measures. As most healthcare officials and pharmaceutical MA&P decision makers have primary responsibility for the pharmaceutical cost, budget impact analyses play a key role in the assessment of a new drug.
